Stock Chart

GH

$166.66 +2.50%
Score: 61.2 BUY
LEAPs: SELL $130
i
LEAPs Option Signal

Type: SELL wallstreet
Strike: $130
Premium: $7.95
Expiry: Jan 15, 2027
Target: $133
Score: -68

LEAPs are long-term options (1+ year) with less time decay.
Pro
Screener
Vol: 1.46x (vs SPY: 1.9x | vs QQQ: 1.6x)
Volume Ratio Explained

Vol: Current volume vs 20-day average
vs SPY: Relative activity vs market
vs QQQ: Relative activity vs tech

Color Guide:
● Red (≥1.5x): High activity
● Yellow (≥1.2x): Above average
● Blue (≤0.7x): Low activity

Interpretation:
• vs SPY > 1: Stock-specific interest
• vs SPY < 1: Stock quiet vs market
Chart Pattern · as of Oct 21, 2026
Descending Triangle weak / forming — below our quality gate quality 56/100
A Descending Triangle is taking shape but hasn't passed our quality gate (60/100), so no projected path or levels are shown — only the forming rails on the chart below.
Break direction historically ~even (52% up, n=87) — scenario shown, not a forecast
Technical Chart
CHART OVERLAYS
Active: 2
INDICATORS
TRENDLINES
OPTIONS FLOW
VOLUME & PRICE
OTHER

About GH - Guardant Health, Inc. Common Stock

Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a …

Key Statistics

Market Cap $22B

This GH stock chart provides comprehensive technical analysis including candlestick patterns, volume profile analysis, and options open interest data. Track GH's price movements with trendlines, gamma walls, and key support/resistance levels.